Drug Profile
ABNCoV2 cVLP based COVID-2019 vaccine - AdaptVac
Alternative Names: ABNCoV2; ABNCoV2 Vaccine; ABNCoV2-cVLP based COVID-19 vaccine; Coronavirus vaccine - AdaptVac; COVID-19 cVLP vaccine - AdaptVac; COVID-19 vaccine - AdaptVac; cVLP-RBD; RBDn-CLPLatest Information Update: 23 Jan 2023
Price :
$50
*
At a glance
- Originator AdaptVac
- Developer AdaptVac; Bavarian Nordic
- Class COVID-19 vaccines; Subunit vaccines; Synthetic vaccines; Viral vaccines; Virus-like particle vaccines
- Mechanism of Action Immunostimulants
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- Phase II COVID 2019 infections
Most Recent Events
- 23 Jan 2023 Bavarian Nordic completes phase-II trial in COVID-2019 infections (Prevention) in Germany (IM) (NCT05077267) (EudraCT2021-001393-31) (AdaptVac pipeline; January 2023)
- 19 Oct 2022 AdaptVac complete enrolment in its phase II trial in Covid-2019 infections in Germany
- 17 Oct 2022 Updated immunogenicity data from a phase II trial in Covid-2019 infections released by Bavarian Nordic